Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer.

BioMed research international - 1 Jan 2015

Wilkins Anna, Dearnaley David, Somaiah Navita

Abstract excerpt

Localised prostate cancer, in particular, intermediate risk disease, has varied survival outcomes that cannot be predicted accurately using current clinical risk factors. External beam radiotherapy (EBRT) is one of the standard curative treatment options for localised disease and its efficacy is related to wide ranging aspects of tumour biology. Histopathological techniques including immunohistochemistry and a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Evidence-Based Medicine
Share to Genetic Markers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Proteins

Share to Prevalence

Share to Prostatic Neoplasms

Share to Risk Assessment

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26504789
DOI: 10.1155/2015/238757
PMCID: PMC4609338

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer.PMID 26504789Read ↗

Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancerSemantic proximity Read ↗

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.Semantic proximity Read ↗

Molecular Genetics of Prostate Cancer and Role of Genomic TestingSemantic proximity Read ↗

Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized TherapySemantic proximity Read ↗

Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature.Semantic proximity Read ↗

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic PrognosticatorsSemantic proximity Read ↗

Bad neighbours: hypoxia and genomic instability in prostate cancerSemantic proximity Read ↗

Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.Semantic proximity Read ↗

Genomic biomarkers in prostate cancerSemantic proximity Read ↗

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.Semantic proximity Read ↗

Uncovering the Secrets of Prostate Cancer’s Radiotherapy Resistance: Advances in Mechanism ResearchSemantic proximity Read ↗

Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.